Cuban Meningococcal BC Vaccine: Experiences & Contributions from 20 Years of Application
Fuente:
Redalyc
Salvato in:
| Autore principale: | |
|---|---|
| Natura: | Artículo científico |
| Lingua: | en |
| Pubblicazione: |
Medical Education Cooperation with Cuba
2007
|
| Soggetti: | |
| Accesso online: | |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
| _version_ | 1876484539287601152 |
|---|---|
| author | Franklin Sotolongo Padrón |
| author_facet | Franklin Sotolongo Padrón |
| contents | Cuban Meningococcal BC Vaccine: Experiences & Contributions from 20 Years of Application Franklin Sotolongo Padrón Concepción Campa Huergo Victoria Casanueva Gil Esther María Fajardo Díaz Iván Edelberto Cuevas Valdespino Noel González Gotera Medicina BC® VAMENGOC Meningitis meningococcal disease meningococcal vaccine This paper reviews 20 years of experience and scientific contributions of the Cuban meningococcal BC vaccine (VA-MENGOC-BC®) obtained by the Finlay Institute in Havana, Cuba. The vaccine is the first of its type in the world that is safe, effective, and commercially available for preventing meningococcal disease caused by serogroup B meningococcus; it is also effective against serogroup C. VA-MENGOC-BC® has shown satisfactory results, with no serious adverse events, after application of approximately 55 million doses in some 15 countries. Also included is background information on meningococcal disease, as well as the main characteristics of VA-MENGOC-BC®, the strategy used for controlling meningococcal disease and its prevention in Cuba, and a summary of the main scientific results obtained in basic research, development, clinical evaluation, and post-marketing results (safety, efficacy-effectiveness, post-vaccination adverse events, etc.) in Cuba and elsewhere. 2007 artículo científico 1555-7960 https://www.redalyc.org/articulo.oa?id=437542063006 en http://www.redalyc.org/revista.oa?id=4375 MEDICC Review application/pdf Medical Education Cooperation with Cuba MEDICC Review (Estados Unidos de América) Num.1 Vol.9 |
| format | Artículo científico |
| id | redalyc_437542063006 |
| institution | Redalyc |
| language | en |
| publishDate | 2007 |
| publisher | Medical Education Cooperation with Cuba |
| spellingShingle | Cuban Meningococcal BC Vaccine: Experiences & Contributions from 20 Years of Application Franklin Sotolongo Padrón Medicina BC® VAMENGOC Meningitis meningococcal disease meningococcal vaccine Cuban Meningococcal BC Vaccine: Experiences & Contributions from 20 Years of Application Franklin Sotolongo Padrón Concepción Campa Huergo Victoria Casanueva Gil Esther María Fajardo Díaz Iván Edelberto Cuevas Valdespino Noel González Gotera Medicina BC® VAMENGOC Meningitis meningococcal disease meningococcal vaccine This paper reviews 20 years of experience and scientific contributions of the Cuban meningococcal BC vaccine (VA-MENGOC-BC®) obtained by the Finlay Institute in Havana, Cuba. The vaccine is the first of its type in the world that is safe, effective, and commercially available for preventing meningococcal disease caused by serogroup B meningococcus; it is also effective against serogroup C. VA-MENGOC-BC® has shown satisfactory results, with no serious adverse events, after application of approximately 55 million doses in some 15 countries. Also included is background information on meningococcal disease, as well as the main characteristics of VA-MENGOC-BC®, the strategy used for controlling meningococcal disease and its prevention in Cuba, and a summary of the main scientific results obtained in basic research, development, clinical evaluation, and post-marketing results (safety, efficacy-effectiveness, post-vaccination adverse events, etc.) in Cuba and elsewhere. 2007 artículo científico 1555-7960 https://www.redalyc.org/articulo.oa?id=437542063006 en http://www.redalyc.org/revista.oa?id=4375 MEDICC Review application/pdf Medical Education Cooperation with Cuba MEDICC Review (Estados Unidos de América) Num.1 Vol.9 |
| title | Cuban Meningococcal BC Vaccine: Experiences & Contributions from 20 Years of Application |
| topic | Medicina BC® VAMENGOC Meningitis meningococcal disease meningococcal vaccine |
| url | https://www.redalyc.org/articulo.oa?id=437542063006 |